Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - amphotericin b - powder for solution for infusion - amphotericin b 50 mg - antimycotics for systemic use

United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 12.5 ml - amb isome is indicated for the following: see dosage and administration for recommended doses by indication. amb isome is contraindicated in those patients who have demonstrated or have a known hypersensitivity to amphotericin b deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.

United States - English - NLM (National Library of Medicine)

leadiant biosciences, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe), dimyristoylphosphatidylcholine, dl- (unii: u86zgc74v5) (dimyristoylphosphatidylcholine, dl- - unii:u86zgc74v5), dimyristoylphosphatidylglycerol, dl- (unii: bi71wt9p3r) (dimyristoylphosphatidylglycerol, dl- - unii:bi71wt9p3r) - amphotericin b 5 mg in 1 ml - abelcet ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin b therapy. this is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin b therapy (see description of clinical studies). description of clinical studies fungal infections data from 473 patients were pooled from three open-label studies in which abelcet ® was provided for the treatment of patients with invasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin b, or who had preexisting nephrotoxicity. results of these studies demonstrated effectiveness of abelcet ® in the treatment of invasive fungal infections as a second line therapy. patients were defined by their individual physician as being refractory to or failing conventional amphotericin b therapy based on overall clinical judgement after receiving a minimu

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amphotericin b (amphotericin) -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: cholesterol; sodium succinate hexahydrate; dl-alpha-tocopherol; sucrose; hydrogenated soy phosphatidylcholine; sodium hydroxide; hydrochloric acid; 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium - amphotericin liposomal ran is indicated for:,? prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for,? the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see section 5.1 pharmacodynamic properties, clinical trials).,amphotericin liposomal ran is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment.,amphotericin liposomal ran is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium; dl-alpha-tocopherol; hydrogenated soy phosphatidylcholine; cholesterol; hydrochloric acid; sodium succinate hexahydrate; sucrose; sodium hydroxide - amphotericin liposomal rbx is indicated for:,? prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for,? the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see section 5.1 pharmacodynamic properties, clinical trials).,amphotericin liposomal rbx is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment.,amphotericin liposomal rbx is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; cholesterol; 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium; sodium succinate hexahydrate; sucrose; sodium hydroxide; dl-alpha-tocopherol; hydrochloric acid - amphotericin liposomal sun is indicated for:,? prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for,? the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see section 5.1 pharmacodynamic properties, clinical trials).,amphotericin liposomal sun is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment.,amphotericin liposomal sun is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Ireland - English - HPRA (Health Products Regulatory Authority)

gilead sciences international - amphotericin b - concentrate for soln for inf - 50 milligram - antibiotics

United States - English - NLM (National Library of Medicine)

intermune, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - injection, lipid complex - 50 mg in 10 ml - amphotec is indicated for the treatment of invasive aspergillosis in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin b deoxycholate therapy has failed. amphotec should not be administered to patients who have documented hypersensitivity to any of its components, unless, in the opinion of the physician, the advantages of using amphotec outweigh the risks of hypersensitivity.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amphotericin b - eye drops - 1.5mg/1ml